Guardant Health officer plans $632K share sale

An officer of Guardant Health (GH) has filed a Rule 144 notice to sell 4,000 shares of common stock, after a prior 3,418-share sale in June 2026.

Rhea-AI Filing Summary

Guardant Health, Inc. (GH) has an officer, Kumud Kalia, filing a Rule 144 notice to sell 4,000 shares of common stock of Guardant Health through Charles Schwab & Co., Inc. The planned sale, listed on NASDAQ, is tied to shares acquired via equity compensation between April 1, 2025 and October 1, 2025.

The filing also reports that Kalia previously sold 3,418 shares of Guardant Health common stock on June 11, 2026 for aggregate proceeds of $445,156. The new 4,000-share sale is valued in the notice at $632,193 as of September 11, 2026.

Key Figures

Shares proposed for sale: 4,000 shares Proposed sale value: $632,193 Shares sold in prior transaction: 3,418 shares +2 more

5 metrics

Shares proposed for sale 4,000 shares Guardant Health common stock under Rule 144 by officer Kumud Kalia

Proposed sale value $632,193 Aggregate value of 4,000 Guardant Health shares as of September 11, 2026

Shares sold in prior transaction 3,418 shares Guardant Health common stock sold on June 11, 2026

Value of prior sale $445,156 Aggregate proceeds from 3,418 shares sold on June 11, 2026

Acquisition period for shares April 1, 2025 to October 1, 2025 Period when the shares in this filing were acquired and paid for

Key Terms

Rule 144, Restricted Stock Lapse, Equity Compensation

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Lapse financial

"Common | 04/01/2025 | Restricted Stock Lapse - See Remarks |"

Equity Compensation financial

"4000 | 04/01/2025 | Equity Compensation"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Guardant Health (GH)?

The filing discloses that officer Kumud Kalia plans to sell 4,000 shares of Guardant Health common stock under Rule 144, held at Charles Schwab & Co., with an indicated value of $632,193 as of September 11, 2026.

How many Guardant Health (GH) shares did Kumud Kalia sell recently?

The notice reports that 3,418 shares of Guardant Health common stock were sold on June 11, 2026, for aggregate proceeds of $445,156, and the current Form 144 covers an additional 4,000 shares proposed for sale.

What is the value of the Guardant Health (GH) shares covered by this Form 144?

The 4,000 Guardant Health common shares covered by this Form 144 are listed with an aggregate value of $632,193 as of September 11, 2026, based on the market information reported in the notice.

How and when were the Guardant Health (GH) shares to be sold acquired?

According to the remarks, the shares to be sold in this filing were acquired and paid for between April 1, 2025 and October 1, 2025, and are linked to restricted stock lapse and equity compensation from Guardant Health.

On which market will the Guardant Health (GH) shares be sold under this Form 144?

The Form 144 indicates that the Guardant Health common stock covered by the filing is listed for trading on the NASDAQ, with Charles Schwab & Co., Inc. identified as the broker handling the 4,000-share proposed sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 04:50 PM Accepted by SEC EDGAR 09/11/2026 - 04:50 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001927831
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Guardant Health, Inc.
SEC File Number	001-38683
Address of Issuer	3100 HANOVER STREET PALO ALTO CALIFORNIA 94304
Phone	855-698-8887
Name of Person for Whose Account the Securities are To Be Sold	Kalia Kumud
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	4000	632193.00	134196170	09/11/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	04/01/2025	Restricted Stock Lapse - See Remarks	Guardant Health, Inc.			4000	04/01/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
KUMUD KALIA 3100 HANOVER STREET PALO ALTO CA 94304	Guardant Health, Inc.	06/11/2026	3418	445156.00

144: Remarks and Signature

Remarks	Shares sold in this filing were acquired and paid for between 04/01/2025 and 10/01/2025.
Date of Notice	09/11/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	KUMUD KALIA
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)